Accuray Inc
NASDAQ:ARAY
Accuray Inc
Accuray, Inc. is a radiation oncology company. The company is headquartered in Sunnyvale, California and currently employs 995 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The firm's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Accuray, Inc. is a radiation oncology company. The company is headquartered in Sunnyvale, California and currently employs 995 full-time employees. The company went IPO on 2007-02-08. The firm develops, manufactures, sells and supports market-changing solutions that are designed to deliver radiation treatments. The firm's technologies include the CyberKnife and TomoTherapy platforms, including the Radixact System. The CyberKnife and TomoTherapy platform, which are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT) and adaptive radiation therapy (ART). The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Guidance Cut: Accuray lowered its fiscal 2026 revenue outlook to $440–450 million and adjusted EBITDA to $22–25 million, citing ongoing tariffs and geopolitical pressures, especially in China.
Revenue Miss: Q2 revenue was $102.2 million, down 12% year-over-year, mainly due to weaker-than-expected product revenue in China.
Profitability Actions: The company is executing a transformation plan, including a 15% workforce reduction and targeted cost savings, aiming for $25 million in annualized operating profitability improvement.
Margin Pressure: Gross margin fell to 23.5%, impacted by China JV timing, tariffs, and product mix; product gross margins were especially weak.
Service Resilience: Service revenue grew 4% year-over-year, highlighting the recurring revenue strategy's strength despite macro headwinds.
Transformation Progress: Management detailed ongoing strategic, operational, and organizational changes to improve growth, accountability, and execution.
